Due to a lack of funding for pediatric and young adult sarcoma cancer research, treatment options have remained unchanged for over 40 years. Our hope is to improve outcomes for young patients by supporting research and clinical trials focused on safer, more effective treatments.
When Carley learned that her cancer had returned, she desperately wanted a better treatment than more chemo and radiation. She asked her mother to find something, anything other than more chemo and radiation – immune compromising and debilitating treatment that would keep her from going to college and living a normal life. Luckily, Laura found an immunotherapy vaccine trial that helped her body fight the Ewing sarcoma for eight years and live a fulfilled college and post college life.
Unfortunately, the cancer returned in 2020, and Carley passed away at 27, fueling the drive more than ever, to find a curative and less toxic sarcoma treatment.
Research includes development of a personalized immune-enabling vaccine designed for patients with hard-to-cure, metastatic Ewing sarcoma, with the goal of intervening before the cancer recurs.
Phase 2: PEEL 224
Locations: MD Anderson, Dana Faber
Ewing sarcoma
Desmoplastic small round cell tumor
Other sarcoma (any histology, or EWS/DSRCT with evaluable but not measurable disease)
To study the treatment efficacy of zanzalintinib monotherapy in patients with advanced and/or metastatic bone sarcomas.
Location: MD Anderson
Currently Open but not recruiting; check back for updates
Our Research Advisory Team focuses on identifying promising research and new drug developments for pediatric sarcomas that are advancing toward FDA approval and clinical trials.
When selecting projects, we look for three key factors: (1) the treatment must be less toxic and tailored to the individual (2) it must target cancer cells while protecting healthy tissues and organs, and (3) it must boost the immune system to help the body fight the cancer.
In addition to supporting current research projects and clinical trials, Rutledge Cancer Foundation (RCF) is focused on improving efficiencies in the research and biotech communities by bringing together researchers, medical institutions and pharmaceutical companies to work together and more effectively to bring novel therapies to patients more quickly.
We fund patient programs that address unmet emotional and physical needs.
We work as a catalyst to increase awareness and early detection.
We support research for less toxic, personalized cancer therapies.
